|
Status |
Public on Mar 15, 2021 |
Title |
Discovery of tumor specific antigens in acute myeloid leukemia. |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
We performed RNA-Seq and mass spectrometry (MS) on the immunopeptidome of 19 human primary AML samples and discovered a set of 58 tumor specific antigens (TSA) that could serve to design an anti-AML immunotherapy.
|
|
|
Overall design |
Four proteogenomic approaches were used to create cancer-specific MS databases. Peptide identifications were made on the samples used for RNA-Seq and database construction. Various bioinformatic approaches were then performed to establish the TSA nature of the peptides identified by MS. Data reported here are paired-end stranded RNA-sequencing (R1 map on reverse strand and R2 on forward strand) of the 19 AML samples at a coverage >120M reads / sample. MS data are freely available on PRIDE (PXD018542 and 10.6019/PXD018542).
|
|
|
Contributor(s) |
Ehx G, Perreault C |
Citation(s) |
33740418 |
|
Submission date |
Mar 25, 2020 |
Last update date |
Jun 14, 2021 |
Contact name |
Claude Perreault |
E-mail(s) |
[email protected]
|
Organization name |
Institute for Research in Immunology and Cancer
|
Street address |
2950, Chemin de Polytechnique
|
City |
Montréal |
State/province |
Québec |
ZIP/Postal code |
H3C 3J7 |
Country |
Canada |
|
|
Platforms (1) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
Samples (19)
|
|
Relations |
BioProject |
PRJNA615163 |
SRA |
SRP254014 |